SynAct Pharma AB (8F8) Ratios
SynAct Pharma AB Ratios
DE:8F8's free cash flow for Q2 2026 was $0.00. For the 2026 fiscal year, DE:8F8's free cash flow was increased by $34.54M and operating cash flow was $-34.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.31 | 3.30 | 3.01 | 9.34 | 2.27 |
| Quick Ratio | 3.31 | 3.30 | 3.01 | 9.34 | 2.25 |
| Cash Ratio | 2.48 | 2.15 | 2.50 | 7.21 | 1.56 |
| Solvency Ratio | -2.19 | -0.14 | -4.15 | -6.10 | -3.96 |
| Operating Cash Flow Ratio | -4.52 | -3.13 | -4.02 | -7.83 | -4.22 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -149.91 | -173.02 | -117.56 | -66.39 |
| Net Current Asset Value | $ 21.12M | $ 37.65M | $ 23.23M | $ 124.16M | $ 17.42M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.08 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.00 | 0.02 | 0.15 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.00 | 0.02 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.26 | 1.29 | 1.13 | 1.84 |
| Debt Service Coverage Ratio | -44.21 | -4.93 | -155.69 | -75.62 | -63.76 |
| Interest Coverage Ratio | -47.80 | -109.73 | -281.68 | -359.54 | -730.47 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.08 | 0.07 | 0.04 | 0.09 | 0.12 |
| Net Debt to EBITDA | 0.44 | 3.85 | 0.28 | 1.00 | 0.27 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 93.14% | 90.73% | 96.23% | 92.66% | 90.23% |
| EBT Per EBIT | 101.57% | 100.94% | 99.90% | 101.29% | 100.14% |
| Return on Assets (ROA) | -50.26% | -30.46% | -94.65% | -69.57% | -180.62% |
| Return on Equity (ROE) | -65.08% | -38.47% | -122.49% | -78.41% | -332.09% |
| Return on Capital Employed (ROCE) | -58.87% | -37.17% | -110.55% | -82.85% | -333.78% |
| Return on Invested Capital (ROIC) | -54.66% | -33.56% | -105.77% | -75.58% | -277.52% |
| Return on Tangible Assets | -152.45% | -71.08% | -284.48% | -69.57% | -180.62% |
| Earnings Yield | -9.60% | -23.24% | -74.14% | -4.41% | -1.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.04 | 0.08 | 0.23 | 0.02 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10262.00 | -4536.70 | -1620.20 | -16624.09 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 1020.34 |
| Days of Payables Outstanding | 0.00 | 10262.00 | 4536.70 | 1620.20 | 17644.43 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 1020.34 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.91 | -2.26 | -3.08 | -4.26 | -2.50 |
| Free Cash Flow Per Share | -1.91 | -2.26 | -3.08 | -4.26 | -2.50 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -53.89 | -47.42 | -157.26 | -56.95 | -21.04 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -8.43% | -25.15% | -34.42% | -5.23% | -1.76% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.41 | -4.31 | -1.35 | -22.66 | -53.36 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.78 | 1.66 | 1.65 | 17.77 | 177.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.86 | -3.98 | -2.91 | -19.12 | -56.89 |
| Price-to-Operating Cash Flow Ratio | -11.86 | -3.98 | -2.91 | -19.12 | -56.89 |
| Price-to-Earnings Growth (PEG) Ratio | -2.41 | 0.06 | -0.02 | -0.65 | -0.46 |
| Enterprise Value Multiple | -9.46 | -19.18 | -1.03 | -20.26 | -47.99 |
| Enterprise Value | 1.10B | 295.28M | 229.32M | 2.14B | 3.68B |
| EV to EBITDA | -9.46 | -19.18 | -1.03 | -20.26 | -47.99 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -11.33 | -3.31 | -2.29 | -18.22 | -56.57 |
| EV to Operating Cash Flow | -11.33 | -3.31 | -2.29 | -18.22 | -56.57 |
| Tangible Book Value Per Share | 0.44 | 1.51 | 0.74 | 4.59 | 0.80 |
| Shareholders’ Equity Per Share | 3.33 | 5.42 | 5.42 | 4.59 | 0.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.07 | 0.09 | 0.04 | 0.07 | 0.10 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.17 | -2.08 | -6.64 | -3.60 | -2.67 |
| Tax Burden | 0.93 | 0.91 | 0.96 | 0.93 | 0.90 |
| Interest Burden | 1.02 | 1.01 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.84 | 0.99 | 0.46 | 1.11 | 0.85 |
Currency in SEK
